Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 04:04 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 1TerminatedINTERVENTIONAL

A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

ClinicalTrials.gov · NCT04253223 · Registry updated: 2021-06-11

Condition / research focus: Hyperglycemia Drug Induced
Sponsor: Duke University
Countries with listed sites: United States
Registry dates and results: Start: 2020-04-07. Completion: 2021-05-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

REMD-477 (biological) — also listed as: Volagidemab

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Duke University Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

ClinicalTrials.gov · NCT03378635 · Registry updated: 2021-06-10

Condition / research focus: Hypoglycemia; Diabetes Mellitus, Type 1
Sponsor: Zealand Pharma
Countries with listed sites: Austria · Canada · Germany · United States
Registry dates and results: Start: 2017-12-07. Completion: 2018-05-25 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dasiglucagon (drug) — also listed as: ZP4207
GlucaGen (drug) — also listed as: GlucaGen HypoKit
Placebo (drug) — also listed as: Placebo for dasiglucagon

Where the study takes place — 5 listed sites

ProSciento
Chula Vista, California, United States
Site recruitment: Not reported
Clinical Research Center, Medizinische Universität Graz
Graz, Austria
Site recruitment: Not reported
LMC Diabetes & Manna Research
Toronto, Canada
Site recruitment: Not reported
Profil
Mainz, Germany
Site recruitment: Not reported
Profil
Neuss, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

ClinicalTrials.gov · NCT03480022 · Registry updated: 2021-06-07

Condition / research focus: Pre Diabetes; Polycystic Ovary Syndrome; Obesity Android
Sponsor: Woman's
Countries with listed sites: United States
Registry dates and results: Start: 2018-09-26. Completion: 2021-05-19 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Pen Injector [Saxenda] (drug) — also listed as: Liraglutide 3mg, Saxenda
Placebo Liraglutide Pen Injector (drug) — also listed as: Placebo Saxenda, Placebo liraglutide 3 mg

Where the study takes place — 1 listed sites

Woman's Hospital
Baton Rouge, Louisiana, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

ClinicalTrials.gov · NCT03232112 · Registry updated: 2021-06-04

Condition / research focus: Alcohol Dependence, in Remission; Addiction, Alcohol
Sponsor: Anders Fink-Jensen, MD, DMSci
Countries with listed sites: Denmark
Registry dates and results: Start: 2017-08-07. Completion: 2020-10-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide 2 MG Injection (drug) — also listed as: Bydureon Pen, 2 Mg, Extended Release
BD PosiFlush (saline) (drug) — also listed as: Saline

Where the study takes place — 1 listed sites

Novavì ambulatorierne
Copenhagen, Frederiksberg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effects of Low/No Calorie Sweeteners on Glucose Tolerance

ClinicalTrials.gov · NCT04904133 · Registry updated: 2021-05-27

Condition / research focus: Healthy Population; Glucose Tolerance
Sponsor: Acibadem University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2019-04-02. Completion: 2019-07-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Low/No Calorie Sweeteners (other)
Placebo Group (other) — also listed as: Control

Where the study takes place — 1 listed sites

Acıbadem Dr. Şinasi Can (Kadıköy) Hospital
Istanbul, Anadolu, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

ClinicalTrials.gov · NCT03688711 · Registry updated: 2021-05-19

Condition / research focus: Hypoglycemia; Diabetes Mellitus, Type 1
Sponsor: Zealand Pharma
Countries with listed sites: United States
Registry dates and results: Start: 2018-11-01. Completion: 2019-03-11 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dasiglucagon (drug) — also listed as: ZP4207
Placebo (drug) — also listed as: Placebo for dasiglucagon

Where the study takes place — 3 listed sites

ProSciento, Inc.
Chula Vista, California, United States
Site recruitment: Not reported
AMCR Institute
Escondido, California, United States
Site recruitment: Not reported
Rainier Clinical Research, Inc.
Renton, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

ClinicalTrials.gov · NCT03311724 · Registry updated: 2021-05-19

Condition / research focus: Type 2 Diabetes
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2017-10-19. Completion: 2018-04-24 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)

Where the study takes place — 13 listed sites

Valley Research
Fresno, California, United States
Site recruitment: Not reported
National Research Institute
Los Angeles, California, United States
Site recruitment: Not reported
Catalina Research Institute, LLC
Montclair, California, United States
Site recruitment: Not reported
University Clinical Investigators, Inc.
Tustin, California, United States
Site recruitment: Not reported
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Site recruitment: Not reported
Suncoast Research Group, LLC
Miami, Florida, United States
Site recruitment: Not reported
Solaris Clinical Research
Meridian, Idaho, United States
Site recruitment: Not reported
Cotton O'Neil Diabetes and Endocrinology Center
Topeka, Kansas, United States
Site recruitment: Not reported
Clinical Research Professionals
St Louis, Missouri, United States
Site recruitment: Not reported
Aventiv Research
Columbus, Ohio, United States
Site recruitment: Not reported
New Phase Research & Development
Knoxville, Tennessee, United States
Site recruitment: Not reported
Dallas Diabetes Endocrine Center
Dallas, Texas, United States
Site recruitment: Not reported
Consano Clinical Research
Shavano Park, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Investigating Brown Adipose Tissue Activation in Humans

ClinicalTrials.gov · NCT01935791 · Registry updated: 2021-05-18

Condition / research focus: Metabolic Diseases
Sponsor: Imperial College London
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2013-07. Completion: 2018-11-05 (may be estimated). Results are posted in this registry.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle (other)
Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon (drug)
Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative (other)
Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control (drug)
Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control (drug)
Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon (drug)
Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control (drug)
Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control (drug)
Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon (drug)

Where the study takes place — 1 listed sites

Imperial College London
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Glucagon Regulation of Glucose Metabolism

ClinicalTrials.gov · NCT04347252 · Registry updated: 2021-05-14

Condition / research focus: Insulin Secretion
Sponsor: David D'Alessio, M.D.
Countries with listed sites: United States
Registry dates and results: Start: 2019-09-24. Completion: 2021-04-16 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon (drug) — also listed as: exendin-(9-39); hyperglycemia

Where the study takes place — 1 listed sites

Duke Center for Living
Durham, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes

ClinicalTrials.gov · NCT03556098 · Registry updated: 2021-05-10

Condition / research focus: Diabetes Mellitus, Type 1
Sponsor: Steno Diabetes Center Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2019-02-22. Completion: 2020-02-11 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucose-dependent insulinotropic peptide (drug)
Glucose-Dependent Insulin-Releasing Hormone[3-30] (drug)
Saline Solution (drug) — also listed as: Placebo

Where the study takes place — 1 listed sites

Steno Diabetes Center Copenhagen, Clinical Metabolic Physiology
Hellerup, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT03893526 · Registry updated: 2021-05-05

Condition / research focus: Type2 Diabetes
Sponsor: University of Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2019-01-25. Completion: 2021-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Entresto (drug)
Sitagliptin (drug)
Valsartan (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Hvidovre Hospital
Hvidovre, RegionH, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism

ClinicalTrials.gov · NCT02944110 · Registry updated: 2021-05-05

Condition / research focus: Diabetes After Total Pancreatectomy
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: No country reported
Registry dates and results: Start: 2016-04. Completion: 2021-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon receptor antagonist LY2409021 (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

ClinicalTrials.gov · NCT03216226 · Registry updated: 2021-05-04

Condition / research focus: Hypoglycemia; Diabetes Mellitus, Type 1
Sponsor: Zealand Pharma
Countries with listed sites: Austria · Canada · Germany · United States
Registry dates and results: Start: 2017-06-28. Completion: 2018-02-13 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

dasiglucagon (drug) — also listed as: ZP4207
GlucaGen (drug) — also listed as: GlucaGen HypoKit

Where the study takes place — 7 listed sites

Compass Research
Orlando, Florida, United States
Site recruitment: Not reported
Advanced Clinical Research
Meridian, Idaho, United States
Site recruitment: Not reported
CRC - Clinical Research Center, Medizinische Universität Graz
Graz, Austria
Site recruitment: Not reported
LMC Manna Research
Barrie, Canada
Site recruitment: Not reported
LMC Calgary
Calgary, Canada
Site recruitment: Not reported
LMC Diabetes & Manna Research
Toronto, Canada
Site recruitment: Not reported
Diabeteszentrum Hamburg West, Gemeinschaftspraxis für Innere Medizin
Hamburg, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

DPP4 Inhibition & Beta Cell Function

ClinicalTrials.gov · NCT02683187 · Registry updated: 2021-05-03

Condition / research focus: Healthy
Sponsor: David D'Alessio, M.D.
Countries with listed sites: United States
Registry dates and results: Start: 2017-03-01. Completion: 2018-03-16 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Active Comparator: Sitagliptin (drug)
Placebo Comparator - No Sitagliptin (drug)

Where the study takes place — 1 listed sites

Leslie Willis
Durham, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Reward Mechanisms in Obesity

ClinicalTrials.gov · NCT03347890 · Registry updated: 2021-04-30

Condition / research focus: Obesity
Sponsor: Zoltan Pataky
Countries with listed sites: Switzerland
Registry dates and results: Start: 2018-03-05. Completion: 2020-03-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo (drug)

Where the study takes place — 1 listed sites

University Hospitals of Geneva
Geneva, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3UnknownINTERVENTIONAL

Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins

ClinicalTrials.gov · NCT03860688 · Registry updated: 2021-04-29

Condition / research focus: Hyperlipidemias
Sponsor: University Health Network, Toronto
Countries with listed sites: Canada
Registry dates and results: Start: 2019-05-01. Completion: 2022-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TED + glucose (drug)

Where the study takes place — 1 listed sites

Tornto General Hospital, UHN
Toronto, Ontario, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Dose Response of Calcium Co-ingested With Protein on GLP-1 Concentrations

ClinicalTrials.gov · NCT03819972 · Registry updated: 2021-04-28

Condition / research focus: GLP-1 Concentration
Sponsor: University of Bath
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2019-02-02. Completion: 2021-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dose response of Capolac® (dietary_supplement)

Where the study takes place — 1 listed sites

Department for Health, University of Bath
Bath, Somerset, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of GIP After a Meal in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT03702660 · Registry updated: 2021-04-27

Condition / research focus: Type2 Diabetes
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2017-08-01. Completion: 2018-01-23 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GIP(3-30)NH2 (other)
Peripheral venous cannulation (other)
GLP-1 (other)

Where the study takes place — 1 listed sites

Center for Diabetes Research, Gentofte Hospital
Hellerup, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

Liraglutide for Low-responders After Bariatric Surgery

ClinicalTrials.gov · NCT04643301 · Registry updated: 2021-04-26

Condition / research focus: Obesity; Obesity, Morbid
Sponsor: Zuyderland Medisch Centrum
Countries with listed sites: No country reported
Registry dates and results: Start: 2020-12-21. Completion: 2021-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Pen Injector (drug) — also listed as: Saxenda

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pilot Data Collection for Activity, Adiposity, and Appetite in Adolescents

ClinicalTrials.gov · NCT03157063 · Registry updated: 2021-04-26

Condition / research focus: Physical Activity; Sedentary Lifestyle; Metabolism; Energy Balance
Sponsor: Children's Mercy Hospital Kansas City
Countries with listed sites: United States
Registry dates and results: Start: 2017-01-01. Completion: 2018-11-19 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Data Collection Procedures (diagnostic_test)

Where the study takes place — 1 listed sites

Children's Mercy Kansas City
Kansas City, Missouri, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-09 04:04 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 1TerminatedINTERVENTIONAL

A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

ClinicalTrials.gov · NCT04253223 · Registry updated: 2021-06-11

Condition / research focus: Hyperglycemia Drug Induced
Sponsor: Duke University
Countries with listed sites: United States
Registry dates and results: Start: 2020-04-07. Completion: 2021-05-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

REMD-477 (biological) — also listed as: Volagidemab

Where the study takes place — 1 listed sites

Duke University Medical Center
Durham, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

ClinicalTrials.gov · NCT03378635 · Registry updated: 2021-06-10

Condition / research focus: Hypoglycemia; Diabetes Mellitus, Type 1
Sponsor: Zealand Pharma
Countries with listed sites: Austria · Canada · Germany · United States
Registry dates and results: Start: 2017-12-07. Completion: 2018-05-25 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dasiglucagon (drug) — also listed as: ZP4207
GlucaGen (drug) — also listed as: GlucaGen HypoKit
Placebo (drug) — also listed as: Placebo for dasiglucagon

Where the study takes place — 5 listed sites

ProSciento
Chula Vista, California, United States
Site recruitment: Not reported
Clinical Research Center, Medizinische Universität Graz
Graz, Austria
Site recruitment: Not reported
LMC Diabetes & Manna Research
Toronto, Canada
Site recruitment: Not reported
Profil
Mainz, Germany
Site recruitment: Not reported
Profil
Neuss, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS

ClinicalTrials.gov · NCT03480022 · Registry updated: 2021-06-07

Condition / research focus: Pre Diabetes; Polycystic Ovary Syndrome; Obesity Android
Sponsor: Woman's
Countries with listed sites: United States
Registry dates and results: Start: 2018-09-26. Completion: 2021-05-19 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Pen Injector [Saxenda] (drug) — also listed as: Liraglutide 3mg, Saxenda
Placebo Liraglutide Pen Injector (drug) — also listed as: Placebo Saxenda, Placebo liraglutide 3 mg

Where the study takes place — 1 listed sites

Woman's Hospital
Baton Rouge, Louisiana, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

ClinicalTrials.gov · NCT03232112 · Registry updated: 2021-06-04

Condition / research focus: Alcohol Dependence, in Remission; Addiction, Alcohol
Sponsor: Anders Fink-Jensen, MD, DMSci
Countries with listed sites: Denmark
Registry dates and results: Start: 2017-08-07. Completion: 2020-10-05 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Exenatide 2 MG Injection (drug) — also listed as: Bydureon Pen, 2 Mg, Extended Release
BD PosiFlush (saline) (drug) — also listed as: Saline

Where the study takes place — 1 listed sites

Novavì ambulatorierne
Copenhagen, Frederiksberg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effects of Low/No Calorie Sweeteners on Glucose Tolerance

ClinicalTrials.gov · NCT04904133 · Registry updated: 2021-05-27

Condition / research focus: Healthy Population; Glucose Tolerance
Sponsor: Acibadem University
Countries with listed sites: Turkey (Türkiye)
Registry dates and results: Start: 2019-04-02. Completion: 2019-07-02 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Low/No Calorie Sweeteners (other)
Placebo Group (other) — also listed as: Control

Where the study takes place — 1 listed sites

Acıbadem Dr. Şinasi Can (Kadıköy) Hospital
Istanbul, Anadolu, Turkey (Türkiye)
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

ClinicalTrials.gov · NCT03688711 · Registry updated: 2021-05-19

Condition / research focus: Hypoglycemia; Diabetes Mellitus, Type 1
Sponsor: Zealand Pharma
Countries with listed sites: United States
Registry dates and results: Start: 2018-11-01. Completion: 2019-03-11 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dasiglucagon (drug) — also listed as: ZP4207
Placebo (drug) — also listed as: Placebo for dasiglucagon

Where the study takes place — 3 listed sites

ProSciento, Inc.
Chula Vista, California, United States
Site recruitment: Not reported
AMCR Institute
Escondido, California, United States
Site recruitment: Not reported
Rainier Clinical Research, Inc.
Renton, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

ClinicalTrials.gov · NCT03311724 · Registry updated: 2021-05-19

Condition / research focus: Type 2 Diabetes
Sponsor: Eli Lilly and Company
Countries with listed sites: United States
Registry dates and results: Start: 2017-10-19. Completion: 2018-04-24 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tirzepatide (drug) — also listed as: LY3298176
Placebo (drug)

Where the study takes place — 13 listed sites

Valley Research
Fresno, California, United States
Site recruitment: Not reported
National Research Institute
Los Angeles, California, United States
Site recruitment: Not reported
Catalina Research Institute, LLC
Montclair, California, United States
Site recruitment: Not reported
University Clinical Investigators, Inc.
Tustin, California, United States
Site recruitment: Not reported
Chase Medical Research, LLC
Waterbury, Connecticut, United States
Site recruitment: Not reported
Suncoast Research Group, LLC
Miami, Florida, United States
Site recruitment: Not reported
Solaris Clinical Research
Meridian, Idaho, United States
Site recruitment: Not reported
Cotton O'Neil Diabetes and Endocrinology Center
Topeka, Kansas, United States
Site recruitment: Not reported
Clinical Research Professionals
St Louis, Missouri, United States
Site recruitment: Not reported
Aventiv Research
Columbus, Ohio, United States
Site recruitment: Not reported
New Phase Research & Development
Knoxville, Tennessee, United States
Site recruitment: Not reported
Dallas Diabetes Endocrine Center
Dallas, Texas, United States
Site recruitment: Not reported
Consano Clinical Research
Shavano Park, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Investigating Brown Adipose Tissue Activation in Humans

ClinicalTrials.gov · NCT01935791 · Registry updated: 2021-05-18

Condition / research focus: Metabolic Diseases
Sponsor: Imperial College London
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2013-07. Completion: 2018-11-05 (may be estimated). Results are posted in this registry.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle (other)
Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon (drug)
Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative (other)
Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control (drug)
Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control (drug)
Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon (drug)
Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control (drug)
Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control (drug)
Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon (drug)

Where the study takes place — 1 listed sites

Imperial College London
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Glucagon Regulation of Glucose Metabolism

ClinicalTrials.gov · NCT04347252 · Registry updated: 2021-05-14

Condition / research focus: Insulin Secretion
Sponsor: David D'Alessio, M.D.
Countries with listed sites: United States
Registry dates and results: Start: 2019-09-24. Completion: 2021-04-16 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon (drug) — also listed as: exendin-(9-39); hyperglycemia

Where the study takes place — 1 listed sites

Duke Center for Living
Durham, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes

ClinicalTrials.gov · NCT03556098 · Registry updated: 2021-05-10

Condition / research focus: Diabetes Mellitus, Type 1
Sponsor: Steno Diabetes Center Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2019-02-22. Completion: 2020-02-11 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

glucose-dependent insulinotropic peptide (drug)
Glucose-Dependent Insulin-Releasing Hormone[3-30] (drug)
Saline Solution (drug) — also listed as: Placebo

Where the study takes place — 1 listed sites

Steno Diabetes Center Copenhagen, Clinical Metabolic Physiology
Hellerup, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT03893526 · Registry updated: 2021-05-05

Condition / research focus: Type2 Diabetes
Sponsor: University of Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2019-01-25. Completion: 2021-03-01 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Entresto (drug)
Sitagliptin (drug)
Valsartan (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Hvidovre Hospital
Hvidovre, RegionH, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism

ClinicalTrials.gov · NCT02944110 · Registry updated: 2021-05-05

Condition / research focus: Diabetes After Total Pancreatectomy
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: No country reported
Registry dates and results: Start: 2016-04. Completion: 2021-07 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Glucagon receptor antagonist LY2409021 (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

ClinicalTrials.gov · NCT03216226 · Registry updated: 2021-05-04

Condition / research focus: Hypoglycemia; Diabetes Mellitus, Type 1
Sponsor: Zealand Pharma
Countries with listed sites: Austria · Canada · Germany · United States
Registry dates and results: Start: 2017-06-28. Completion: 2018-02-13 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

dasiglucagon (drug) — also listed as: ZP4207
GlucaGen (drug) — also listed as: GlucaGen HypoKit

Where the study takes place — 7 listed sites

Compass Research
Orlando, Florida, United States
Site recruitment: Not reported
Advanced Clinical Research
Meridian, Idaho, United States
Site recruitment: Not reported
CRC - Clinical Research Center, Medizinische Universität Graz
Graz, Austria
Site recruitment: Not reported
LMC Manna Research
Barrie, Canada
Site recruitment: Not reported
LMC Calgary
Calgary, Canada
Site recruitment: Not reported
LMC Diabetes & Manna Research
Toronto, Canada
Site recruitment: Not reported
Diabeteszentrum Hamburg West, Gemeinschaftspraxis für Innere Medizin
Hamburg, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

DPP4 Inhibition & Beta Cell Function

ClinicalTrials.gov · NCT02683187 · Registry updated: 2021-05-03

Condition / research focus: Healthy
Sponsor: David D'Alessio, M.D.
Countries with listed sites: United States
Registry dates and results: Start: 2017-03-01. Completion: 2018-03-16 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Active Comparator: Sitagliptin (drug)
Placebo Comparator - No Sitagliptin (drug)

Where the study takes place — 1 listed sites

Leslie Willis
Durham, North Carolina, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4CompletedINTERVENTIONAL

Reward Mechanisms in Obesity

ClinicalTrials.gov · NCT03347890 · Registry updated: 2021-04-30

Condition / research focus: Obesity
Sponsor: Zoltan Pataky
Countries with listed sites: Switzerland
Registry dates and results: Start: 2018-03-05. Completion: 2020-03-30 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo (drug)

Where the study takes place — 1 listed sites

University Hospitals of Geneva
Geneva, Switzerland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2 / Phase 3UnknownINTERVENTIONAL

Effects of Oral Glucose and Teduglutide on Plasma Lipoproteins

ClinicalTrials.gov · NCT03860688 · Registry updated: 2021-04-29

Condition / research focus: Hyperlipidemias
Sponsor: University Health Network, Toronto
Countries with listed sites: Canada
Registry dates and results: Start: 2019-05-01. Completion: 2022-05 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TED + glucose (drug)

Where the study takes place — 1 listed sites

Tornto General Hospital, UHN
Toronto, Ontario, Canada
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

The Dose Response of Calcium Co-ingested With Protein on GLP-1 Concentrations

ClinicalTrials.gov · NCT03819972 · Registry updated: 2021-04-28

Condition / research focus: GLP-1 Concentration
Sponsor: University of Bath
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2019-02-02. Completion: 2021-03-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Dose response of Capolac® (dietary_supplement)

Where the study takes place — 1 listed sites

Department for Health, University of Bath
Bath, Somerset, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effect of GIP After a Meal in Patients With Type 2 Diabetes

ClinicalTrials.gov · NCT03702660 · Registry updated: 2021-04-27

Condition / research focus: Type2 Diabetes
Sponsor: University Hospital, Gentofte, Copenhagen
Countries with listed sites: Denmark
Registry dates and results: Start: 2017-08-01. Completion: 2018-01-23 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GIP(3-30)NH2 (other)
Peripheral venous cannulation (other)
GLP-1 (other)

Where the study takes place — 1 listed sites

Center for Diabetes Research, Gentofte Hospital
Hellerup, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

Liraglutide for Low-responders After Bariatric Surgery

ClinicalTrials.gov · NCT04643301 · Registry updated: 2021-04-26

Condition / research focus: Obesity; Obesity, Morbid
Sponsor: Zuyderland Medisch Centrum
Countries with listed sites: No country reported
Registry dates and results: Start: 2020-12-21. Completion: 2021-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Liraglutide Pen Injector (drug) — also listed as: Saxenda

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pilot Data Collection for Activity, Adiposity, and Appetite in Adolescents

ClinicalTrials.gov · NCT03157063 · Registry updated: 2021-04-26

Condition / research focus: Physical Activity; Sedentary Lifestyle; Metabolism; Energy Balance
Sponsor: Children's Mercy Hospital Kansas City
Countries with listed sites: United States
Registry dates and results: Start: 2017-01-01. Completion: 2018-11-19 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Data Collection Procedures (diagnostic_test)

Where the study takes place — 1 listed sites

Children's Mercy Kansas City
Kansas City, Missouri, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →